Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event
As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern.
Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains.
“We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the global economy with rules being rewritten in real time and disruption being the only constant.”
Kinaxis is at the forefront of helping companies of all industries and sizes respond to today’s tariff disruptions. Its leading AI-powered orchestration platform Maestro™ seamlessly connects all supply chain functions to create visibility, collaboration, and smarter decision making in the face of any disruption. During the U.S. presidential election, there was a dramatic increase in the number of what-if scenarios that companies ran on Maestro as they modeled and actioned potential impacts to sourcing, production, and logistics.
“The practice of supply chain management has fundamentally evolved, and disruptions like tariffs demonstrate the need for a modern approach that emphasizes speed, agility, and precision,” said Andrew Bell, chief product officer at Kinaxis. “The speakers joining me during this discussion have made transformative supply chain change and bring first-hand experience around how they are using this new approach to navigate today’s complex challenges. I look forward to highlighting their stories and to helping other companies take steps to better prepare their supply chains for today’s realities.”
Expert guest speakers include:
- Andrew Busch, economic futurist and economist, will speak about the geopolitical and economic outlook on tariff policy, including insights into U.S.-China relations, global decoupling, and the future of trade
- Brent Wilson, senior vice president global supply chain, Qualcomm will share his experiences navigating tariff-driven disruption and building supply chain resilience
- Mark Walker, vice president supply chain, Viant Medical will share his experience strengthening the complex supply chain of Viant Medical through effective planning
- Ken Vandrak, senior director, distribution and logistics, Thermo Fisher Scientific will discuss his experience in navigating the evolving trade landscape and overcoming logistical challenges in global distribution
- Andrew Bell, chief product officer, Kinaxis will share his perspective on the role of AI, automation, and scenario planning in supply chains to drive faster, smarter decision making
Webinar: Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges
Date: Tuesday, June 17
Time: 11:00 AM ET
Registration Link: HERE
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612438708/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917.446.7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Technology Reply earns Oracle Service Expertise in Artificial Intelligence for the Western Europe region13.6.2025 11:00:00 EEST | Press release
Technology Reply, a company of the Reply Group specialising in the design of solutions based on Oracle technologies, has been presented with the Oracle Service Expertise in Artificial Intelligence for the Western Europe region, further consolidating its position as a key partner for AI projects on Oracle Cloud Infrastructure (OCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613439196/en/ Thanks to this certification, Technology Reply strengthens its role as a technology partner for companies seeking to enhance their enterprise applications, improve user interaction, and accelerate decision-making processes through artificial intelligence and Oracle technologies. The Service Expertise certification is in recognition of Technology Reply’s technical and design capabilities in building solutions based on OCI’s AI services, including the use of pre-trained models, chatbot development, custom model creation, and the adoptio
Lone Star Announces Sale of novobanco to BPCE13.6.2025 10:00:00 EEST | Press release
Nani Holdings S.à. r.l., an affiliate of Lone Star Funds (“Lone Star”), today announced that it has signed a Memorandum of Understanding for the sale of Novo Banco, S.A. (“novobanco” or “the bank”), Portugal’s fourth-largest bank, to BPCE, a leading European banking institution, for a cash consideration payable at closing which values 100% of the share capital at an estimated €6.4 billion as of end 2025. This transaction marks the culmination of a multi-year transformation of novobanco since Lone Star acquired 75% of the bank in 2017. Under Lone Star’s stewardship, in cooperation with other shareholders, novobanco has undergone a comprehensive turn-around, establishing itself as one of the most profitable banks in Europe, with a target return on tangible equity (RoTE) exceeding 20%. The bank has significantly de-risked its balance sheet, reducing non-performing loans to de minimis levels, and has made substantial investments in digital transformation and customer experience. Throughout
xFusion Unveils Breakthrough High-Performance Computing Innovations at ISC 202513.6.2025 06:33:00 EEST | Press release
xFusion International Pte. Ltd (xFusion) showcased its latest advancements in high-performance computing (HPC) and sustainable intelligent computing solutions at the International Supercomputing Conference (ISC) 2025, held from June 10 to 13 in Hamburg, Germany. As a global leader in HPC and computing infrastructure, xFusion highlighted its commitment to empowering industries and institutions with cutting-edge technologies that accelerate innovation and digital transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612879566/en/ Arthur Wang Revolutionizing Computing with Innovative Solutions At the Vendor Roadmap Session on June 12, Arthur Wang, Director of xFusion Computing Solution, delivered a compelling keynote titled "Innovative Computing with xFusion." Arthur emphasized the increasing demand for computing power in the age of AI and intelligent agents, as well as xFusion’s role in addressing these challenges.
Kao Releases the Kao Integrated Report 202513.6.2025 05:00:00 EEST | Press release
Kao Corporation (TOKYO:4452) has published the Kao Integrated Report 2025 on its website, offering shareholders, investors, and all stakeholders with a comprehensive overview of the company’s initiatives and strategic direction. Kao Integrated Report 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609991718/en/ The cover visual represents our “moonshot.” It embodies our commitment to achieving the ambitious goal of a sustainable society for future generations. To achieve its Mid-term Plan “K27,” Kao aims to become a unique presence indispensable to someone in the world and is advancing its Global Sharp Top strategy. In FY2024, Kao exceeded its targets by strengthening Return on Invested Capital (ROIC) management and strategically investing to build stronger, more robust businesses. This report offers an in-depth look at Kao’s progress under K27, highlighting how Kao’s dedicated employees—through the Global Sharp Top s
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom